Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%71 PB Ratio is 2.35 as of Jul. 21, 2026, which is 47% above its 10-year median of 1.60. GuruFocus rates CPHGF with a GF Score™ of 71/100 and a GF Value™ of $1.11 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 921 Drug Manufacturers companies, Consun Pharmaceutical Group ranks worse than 58.09% on this metric.
Consun Pharmaceutical Group Ltd stock PB Ratio (=2.28) is close to 1-year low of 2.09.
The historical rank and industry rank for Consun Pharmaceutical Group's PB Ratio or its related term are showing as below:
CPHGF'
s PB Ratio Range Over the Past 10 Years
Min: 0.78 Med: 1.6 Max: 3.87
Current: 2.28
During the past 13 years, Consun Pharmaceutical Group's highest PB Ratio was 3.87. The lowest was 0.78. And the median was 1.60.
CPHGF's PB Ratio is ranked worse than 58.09% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs CPHGF: 2.28
During the past 12 months, Consun Pharmaceutical Group's average Book Value Per Share Growth Rate was 15.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 11.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 12.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Consun Pharmaceutical Group was 64.60% per year. The lowest was 8.10% per year. And the median was 11.10% per year.
Back to Basics: PB Ratio
Consun Pharmaceutical Group (OTCPK:CPHGF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Consun Pharmaceutical Group PB Ratio Related Terms
Consun Pharmaceutical Group PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Consun Pharmaceutical Group (CPHGF) has a PB Ratio of 2.35 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Consun Pharmaceutical Group and its competitors. This is 47% above median its historical median of 1.60. Over the past decade, Consun Pharmaceutical Group's PB Ratio has ranged from 0.78 to 3.87. According to the industry distribution chart, Consun Pharmaceutical Group ranks #535 out of 921 companies in the Drug Manufacturers industry, placing it in the top 58.1%.
Is Consun Pharmaceutical Group's PB Ratio too high?
Consun Pharmaceutical Group's current PB Ratio of 2.35 is 47% above median its 10-year median of 1.60. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 3.87. The Drug Manufacturers industry median PB Ratio is 1.86. Consun Pharmaceutical Group's value of 2.35 is 26.3% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #535 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Consun Pharmaceutical Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #535 out of 921 companies for PB Ratio. This places Consun Pharmaceutical Group in the lower half of its industry. The industry median PB Ratio is 1.86. Consun Pharmaceutical Group's value of 2.35 is 26.3% above this benchmark. Historically, Consun Pharmaceutical Group's own PB Ratio has ranged from 0.78 to 3.87 over the past decade. While the company's 10-year median is 1.60 vs. the industry median of 1.86, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current PB Ratio of 2.35 is 26.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current PB Ratio is 2.35, which is 47% above median its own 10-year median of 1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.11, compared to a current price of $1.80 — trading 62.2% above its estimated fair value. The current PB Ratio is 2.35, which is 47% above median its 10-year median of 1.60 and 26.3% above the Drug Manufacturers industry median of 1.86. Consun Pharmaceutical Group's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current PB Ratio is 2.35 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 62.2% above its estimated GF Value™ of $1.11.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
PB Ratio: 2.35 (47% above median its 10-year median of 1.60)
GF Value™: $1.11 vs. price of $1.80 (62.2% above fair value)
Industry Position: 26.3% above the Drug Manufacturers median (#535 of 921)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
71GF Score
Get the complete analysis for CPHGF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
